000285634 001__ 285634
000285634 005__ 20260313131410.0
000285634 0247_ $$2doi$$a10.1007/s00415-026-13740-1
000285634 0247_ $$2pmid$$apmid:41805906
000285634 0247_ $$2pmc$$apmc:PMC12975812
000285634 0247_ $$2ISSN$$a0367-004X
000285634 0247_ $$2ISSN$$a0012-1037
000285634 0247_ $$2ISSN$$a0340-5354
000285634 0247_ $$2ISSN$$a1432-1459
000285634 037__ $$aDZNE-2026-00273
000285634 041__ $$aEnglish
000285634 082__ $$a610
000285634 1001_ $$0P:(DE-2719)9000329$$aVogel, Adam P$$b0
000285634 245__ $$aDevelopment and validation of the dysarthria impact scale: a patient-reported outcome for motor speech disorders.
000285634 260__ $$a[Darmstadt]$$bSteinkopff$$c2026
000285634 3367_ $$2DRIVER$$aarticle
000285634 3367_ $$2DataCite$$aOutput Types/Journal article
000285634 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1773403877_16829
000285634 3367_ $$2BibTeX$$aARTICLE
000285634 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285634 3367_ $$00$$2EndNote$$aJournal Article
000285634 520__ $$aImpaired speech due to dysarthria significantly impacts quality of life. Patient-reported outcomes (PROs) offer critical insight into the lived experience of communication disability and are central to regulatory frameworks for patient-focused drug development.To develop and validate the Dysarthria Impact Scale (DIS), a brief PRO designed to assess the impact of motor speech disorders on quality of life across neurological conditions.A multi-site, cross-sectional study was conducted with 244 participants, including individuals with Huntington's disease, Parkinson's disease, hereditary ataxias, and head and neck cancer, and healthy controls. The 22-item DIS was developed using expert input and patient feedback and evaluated alongside reference tools (Voice Handicap Index and SF-36). Item reduction procedures yielded two shorter versions (DIS-17 and DIS-6). Validity, reliability, and sensitivity/specificity analyses were performed, and minimal clinically important differences (MCIDs) were estimated using distribution-based methods.All DIS versions showed strong convergent validity with the VHI (r = -0.85) and SF-36 (r = 0.72) and were correlated with blinded perceptual speech ratings. DIS-17 and DIS-6 achieved comparable sensitivity (0.93 and 0.88) and specificity (0.84 and 0.86, respectively). Test-retest reliability was high (r = 0.98), with estimated MCIDs and within-subject variability provided. Group differences were observed, with lower DIS scores in ataxia and Parkinson's disease compared to Huntington's disease.The DIS is a valid, reliable, and practical PRO for quantifying the impact of dysarthria on quality of life. Longitudinal responsiveness remains to be established.
000285634 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285634 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285634 650_7 $$2Other$$aClinical trials
000285634 650_7 $$2Other$$aDysarthria
000285634 650_7 $$2Other$$aPatient-reported outcome
000285634 650_7 $$2Other$$aQuestionnaire
000285634 650_7 $$2Other$$aSpeech
000285634 650_7 $$2Other$$aSurvey
000285634 650_2 $$2MeSH$$aHumans
000285634 650_2 $$2MeSH$$aDysarthria: diagnosis
000285634 650_2 $$2MeSH$$aDysarthria: etiology
000285634 650_2 $$2MeSH$$aDysarthria: psychology
000285634 650_2 $$2MeSH$$aMale
000285634 650_2 $$2MeSH$$aFemale
000285634 650_2 $$2MeSH$$aMiddle Aged
000285634 650_2 $$2MeSH$$aPatient Reported Outcome Measures
000285634 650_2 $$2MeSH$$aAged
000285634 650_2 $$2MeSH$$aCross-Sectional Studies
000285634 650_2 $$2MeSH$$aAdult
000285634 650_2 $$2MeSH$$aReproducibility of Results
000285634 650_2 $$2MeSH$$aQuality of Life
000285634 650_2 $$2MeSH$$aSeverity of Illness Index
000285634 7001_ $$0P:(DE-2719)9001369$$aGraf, Lisa$$b1$$udzne
000285634 7001_ $$aWeiß, Merit$$b2
000285634 7001_ $$aChan, Cheuk S J$$b3
000285634 7001_ $$aHepworth, Graham$$b4
000285634 7001_ $$0P:(DE-2719)2811275$$aSynofzik, Matthis$$b5$$eLast author
000285634 773__ $$0PERI:(DE-600)1421299-7$$a10.1007/s00415-026-13740-1$$gVol. 273, no. 3, p. 195$$n3$$p195$$tJournal of neurology$$v273$$x0367-004X$$y2026
000285634 8564_ $$uhttps://pub.dzne.de/record/285634/files/DZNE-2026-00273.pdf$$yRestricted
000285634 8564_ $$uhttps://pub.dzne.de/record/285634/files/DZNE-2026-00273.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285634 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001369$$aExternal Institute$$b1$$kExtern
000285634 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811275$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000285634 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285634 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-10$$wger
000285634 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-10$$wger
000285634 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-10$$wger
000285634 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-10
000285634 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-10
000285634 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROL : 2022$$d2024-12-10
000285634 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-10
000285634 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-10
000285634 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-10
000285634 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-10
000285634 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-10
000285634 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-10
000285634 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-10
000285634 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-10
000285634 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-10
000285634 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NEUROL : 2022$$d2024-12-10
000285634 9201_ $$0I:(DE-2719)1210000$$kAG Gasser$$lParkinson Genetics$$x0
000285634 980__ $$ajournal
000285634 980__ $$aEDITORS
000285634 980__ $$aVDBINPRINT
000285634 980__ $$aI:(DE-2719)1210000
000285634 980__ $$aUNRESTRICTED